Andrew Smith became Chief Financial Officer and a member of the Executive Management of Santhera on April 1, 2020. He joined Santhera with broad experience in corporate and operational finance in the pharmaceutical and biotech industry, most recently as CFO and COO at Allecra Therapeutics GmbH. Previously, Andrew was CFO of NASDAQ-listed Sucampo Pharmaceuticals Inc., based in the US. During that time, he was involved in a number of capital market transactions in the value of approximately USD 600 million. Prior to that, he held various financial and operations roles focusing on business improvement and transformation where he has gained significant exposure to European and US markets in different organizations with a focus on start-ups, spinoffs and growth.
He is an independent non-executive director on the board of Arix Bioscience plc (LSE: ARIX).
Andrew, a British citizen, is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.